Literature DB >> 21502951

Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice.

E Beurel, L Song, R S Jope.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21502951      PMCID： PMC3200424          DOI： 10.1038/mp.2011.47

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN： 1359-4184            Impact factor:   15.992


× No keyword cloud information.
  10 in total

Review 1.  The glamour and gloom of glycogen synthase kinase-3.

Authors:  Richard S Jope; Gail V W Johnson
Journal:  Trends Biochem Sci       Date:  2004-02       Impact factor: 13.807

2.  mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists.

Authors:  Nanxin Li; Boyoung Lee; Rong-Jian Liu; Mounira Banasr; Jason M Dwyer; Masaaki Iwata; Xiao-Yuan Li; George Aghajanian; Ronald S Duman
Journal:  Science       Date:  2010-08-20       Impact factor: 47.728

3.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

4.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

5.  Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis.

Authors:  Edward J McManus; Kei Sakamoto; Laura J Armit; Leah Ronaldson; Natalia Shpiro; Rodolfo Marquez; Dario R Alessi
Journal:  EMBO J       Date:  2005-03-24       Impact factor: 11.598

6.  A molecular mechanism for the effect of lithium on development.

Authors:  P S Klein; D A Melton
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-06       Impact factor: 11.205

Review 7.  Is glycogen synthase kinase-3 a central modulator in mood regulation?

Authors:  Xiaohua Li; Richard S Jope
Journal:  Neuropsychopharmacology       Date:  2010-07-28       Impact factor: 7.853

Review 8.  Ketamine and the next generation of antidepressants with a rapid onset of action.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy Diazgranados; Carlos A Zarate
Journal:  Pharmacol Ther       Date:  2009-05-03       Impact factor: 12.310

9.  In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors.

Authors:  Patrizia De Sarno; Gautam N Bijur; Anna A Zmijewska; Xiaohua Li; Richard S Jope
Journal:  Neurobiol Aging       Date:  2005-04-26       Impact factor: 4.673

10.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382
  10 in total
  131 in total

Review 1.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

2.  Adiponectin is critical in determining susceptibility to depressive behaviors and has antidepressant-like activity.

Authors:  Jing Liu; Ming Guo; Di Zhang; Shao-Ying Cheng; Meilian Liu; Jun Ding; Philipp E Scherer; Feng Liu; Xin-Yun Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

3.  Ketamine for depression: evidence, challenges and promise.

Authors:  Carlos A Zarate; Mark J Niciu
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

Review 4.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

5.  The antidepressant-like effect of guanosine is dependent on GSK-3β inhibition and activation of MAPK/ERK and Nrf2/heme oxygenase-1 signaling pathways.

Authors:  Priscila B Rosa; Luis E B Bettio; Vivian B Neis; Morgana Moretti; Isabel Werle; Rodrigo B Leal; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2019-11-25       Impact factor: 3.765

6.  Increasing doses of ketamine curtail antidepressant responses and suppress associated synaptic signaling pathways.

Authors:  Ji-Woon Kim; Lisa M Monteggia
Journal:  Behav Brain Res       Date:  2019-11-21       Impact factor: 3.332

7.  Neurobiology of rapid acting antidepressants: role of BDNF and GSK-3β.

Authors:  Ronald S Duman; George K Aghajanian
Journal:  Neuropsychopharmacology       Date:  2014-01       Impact factor: 7.853

Review 8.  Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.

Authors:  Saurabh S Kokane; Ross J Armant; Carlos A Bolaños-Guzmán; Linda I Perrotti
Journal:  Behav Brain Res       Date:  2020-02-13       Impact factor: 3.332

Review 9.  Regulation of inflammation and T cells by glycogen synthase kinase-3: links to mood disorders.

Authors:  Eleonore Beurel
Journal:  Neuroimmunomodulation       Date:  2014-02-14       Impact factor: 2.492

10.  Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.

Authors:  James W Murrough; Andrew M Perez; Sarah Pillemer; Jessica Stern; Michael K Parides; Marije aan het Rot; Katherine A Collins; Sanjay J Mathew; Dennis S Charney; Dan V Iosifescu
Journal:  Biol Psychiatry       Date:  2012-07-27       Impact factor: 13.382
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.